Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising - Redeye
Bildkälla: Stockfoto

Oncopeptides (Q3 Update): Q/Q Growth Only 5%, but 2026 Looks Promising - Redeye

Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Although sales were below our forecast in Q3, we have expectations for higher growth in the coming quarters.

Redeye comments on Oncopeptides’ 3rd quarter report. Sales grew 5% versus Q2 2025. Operating costs amounted to SEK-67m, with an EBIT of SEK-47m. Although sales were below our forecast in Q3, we have expectations for higher growth in the coming quarters.
Börsvärldens nyhetsbrev